NZ588668A - Uses of helicin and other glucopyranosyloxy benzaldehydes in the treatment of cancer - Google Patents
Uses of helicin and other glucopyranosyloxy benzaldehydes in the treatment of cancerInfo
- Publication number
- NZ588668A NZ588668A NZ588668A NZ58866809A NZ588668A NZ 588668 A NZ588668 A NZ 588668A NZ 588668 A NZ588668 A NZ 588668A NZ 58866809 A NZ58866809 A NZ 58866809A NZ 588668 A NZ588668 A NZ 588668A
- Authority
- NZ
- New Zealand
- Prior art keywords
- glucopyranosyloxy
- helicin
- cancer
- treatment
- medicament
- Prior art date
Links
- BGOFCVIGEYGEOF-UHFFFAOYSA-N salicylaldehyde beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1C=O BGOFCVIGEYGEOF-UHFFFAOYSA-N 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- BGOFCVIGEYGEOF-UJPOAAIJSA-N helicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1C=O BGOFCVIGEYGEOF-UJPOAAIJSA-N 0.000 title abstract 2
- 229940068628 helicin Drugs 0.000 title abstract 2
- 150000003935 benzaldehydes Chemical class 0.000 title 1
- -1 bevacizumab Chemical compound 0.000 abstract 4
- 229930012538 Paclitaxel Natural products 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229960001592 paclitaxel Drugs 0.000 abstract 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 abstract 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 abstract 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 abstract 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 abstract 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 abstract 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 abstract 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 abstract 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 abstract 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 abstract 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 abstract 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 abstract 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 abstract 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 abstract 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 abstract 1
- 229960002756 azacitidine Drugs 0.000 abstract 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 abstract 1
- 229960000397 bevacizumab Drugs 0.000 abstract 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 abstract 1
- 229960001467 bortezomib Drugs 0.000 abstract 1
- 229960004117 capecitabine Drugs 0.000 abstract 1
- 229960005395 cetuximab Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960000928 clofarabine Drugs 0.000 abstract 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 abstract 1
- 229960002448 dasatinib Drugs 0.000 abstract 1
- 229960003603 decitabine Drugs 0.000 abstract 1
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 229940108890 emend Drugs 0.000 abstract 1
- 229960005073 erlotinib hydrochloride Drugs 0.000 abstract 1
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960000255 exemestane Drugs 0.000 abstract 1
- OLZAGZCCJJBKNZ-UHFFFAOYSA-N formaldehydephenlyl-O-beta-D-pyranosyl alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=O)C=C1 OLZAGZCCJJBKNZ-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229960002258 fulvestrant Drugs 0.000 abstract 1
- 229960002584 gefitinib Drugs 0.000 abstract 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 abstract 1
- 229960003685 imatinib mesylate Drugs 0.000 abstract 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 abstract 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 abstract 1
- 229960002751 imiquimod Drugs 0.000 abstract 1
- 229960004942 lenalidomide Drugs 0.000 abstract 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 abstract 1
- 229960003881 letrozole Drugs 0.000 abstract 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 229960000801 nelarabine Drugs 0.000 abstract 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 abstract 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 abstract 1
- 229960001756 oxaliplatin Drugs 0.000 abstract 1
- 229960002404 palifermin Drugs 0.000 abstract 1
- 229960001972 panitumumab Drugs 0.000 abstract 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 abstract 1
- 229960001744 pegaspargase Drugs 0.000 abstract 1
- 108010001564 pegaspargase Proteins 0.000 abstract 1
- 229960003349 pemetrexed disodium Drugs 0.000 abstract 1
- 229960004641 rituximab Drugs 0.000 abstract 1
- 229960000487 sorafenib tosylate Drugs 0.000 abstract 1
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 abstract 1
- 229960002812 sunitinib malate Drugs 0.000 abstract 1
- 229960003454 tamoxifen citrate Drugs 0.000 abstract 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 abstract 1
- 229940099419 targretin Drugs 0.000 abstract 1
- 229960004964 temozolomide Drugs 0.000 abstract 1
- 229960003433 thalidomide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4221008P | 2008-04-03 | 2008-04-03 | |
| PCT/US2009/002134 WO2009145841A1 (en) | 2008-04-03 | 2009-04-03 | Compositions and methods for immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ588668A true NZ588668A (en) | 2013-01-25 |
Family
ID=41267359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ588668A NZ588668A (en) | 2008-04-03 | 2009-04-03 | Uses of helicin and other glucopyranosyloxy benzaldehydes in the treatment of cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US20090281047A1 (enExample) |
| EP (1) | EP2271350A4 (enExample) |
| JP (1) | JP2011516478A (enExample) |
| CN (1) | CN102046180A (enExample) |
| AU (1) | AU2009251848A1 (enExample) |
| CA (1) | CA2757437A1 (enExample) |
| IL (1) | IL208445A0 (enExample) |
| MX (1) | MX339451B (enExample) |
| NZ (1) | NZ588668A (enExample) |
| RU (1) | RU2010144744A (enExample) |
| WO (1) | WO2009145841A1 (enExample) |
| ZA (1) | ZA201007830B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100160368A1 (en) | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
| DK2378876T3 (en) | 2008-12-19 | 2019-03-11 | Medicis Pharmaceutical Corp | IMIQUIMOD FORMULATIONS WITH LOWER DOSAGE STRENGTH AND SHORT-TERM DOSAGE PLAN FOR TREATMENT OF ACTINIC KERATOSIS |
| AU2010274097B2 (en) | 2009-07-13 | 2016-06-16 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
| US20140155344A1 (en) * | 2010-06-07 | 2014-06-05 | Neil P. Desai | Combination therapy methods for treating proliferative diseases |
| US20130171279A1 (en) * | 2012-01-04 | 2013-07-04 | Physicianrx, Llc | Composition for Reducing Side- and After-Effects of Cancer Treatment |
| CN103156951A (zh) * | 2013-04-11 | 2013-06-19 | 太仓市胜舟生物技术有限公司 | 一种治疗b细胞淋巴瘤的组合药物 |
| ES2886019T3 (es) * | 2013-12-20 | 2021-12-16 | Campillo Ramiro Moises Vergara | Combinación de piridoxina, ácido fólico e iones magnesio para el tratamiento del cáncer |
| NZ745881A (en) | 2016-02-04 | 2023-04-28 | Auransa Inc | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity |
| EP3493815B1 (en) * | 2016-08-03 | 2022-02-16 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of fosaprepitant and aprepitant |
| CA3108483A1 (en) * | 2017-08-07 | 2019-02-14 | Cognate 3 Llc | Compositions and methods for inducing apoptosis in anaerobic cells and related clinical methods for treating cancer and pathogenic infections |
| WO2022200833A1 (en) * | 2021-03-25 | 2022-09-29 | 2B-Shvat Ltd. | Benzaldehyde extracted from rosales as foodstuff preservative, animal-feed additive, and for treatment of the covid-19 virus |
| JP7018531B1 (ja) | 2021-04-30 | 2022-02-10 | 潤 齋藤 | Ａｘｌ阻害剤 |
| IL315231A (en) * | 2022-02-24 | 2024-10-01 | Shmuel Robinov | Methods of using benzaldehyde preparations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4882314A (en) * | 1985-12-02 | 1989-11-21 | Rikagaku Kenkyusho | A composition and method of treating selected malignant conditions |
| US6407071B1 (en) * | 1998-06-04 | 2002-06-18 | Co-Enzyme Technology Ltd. | Method and composition for treating malignant cells |
| NO309305B1 (no) * | 1999-02-19 | 2001-01-15 | Norsk Hydro As | Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater |
-
2009
- 2009-04-03 RU RU2010144744/15A patent/RU2010144744A/ru not_active Application Discontinuation
- 2009-04-03 US US12/418,342 patent/US20090281047A1/en not_active Abandoned
- 2009-04-03 JP JP2011502995A patent/JP2011516478A/ja active Pending
- 2009-04-03 EP EP09755204A patent/EP2271350A4/en not_active Withdrawn
- 2009-04-03 MX MX2010010866A patent/MX339451B/es active IP Right Grant
- 2009-04-03 WO PCT/US2009/002134 patent/WO2009145841A1/en not_active Ceased
- 2009-04-03 NZ NZ588668A patent/NZ588668A/xx not_active IP Right Cessation
- 2009-04-03 CA CA2757437A patent/CA2757437A1/en not_active Abandoned
- 2009-04-03 CN CN2009801205538A patent/CN102046180A/zh active Pending
- 2009-04-03 AU AU2009251848A patent/AU2009251848A1/en not_active Abandoned
-
2010
- 2010-10-03 IL IL208445A patent/IL208445A0/en unknown
- 2010-11-02 ZA ZA2010/07830A patent/ZA201007830B/en unknown
-
2011
- 2011-08-19 US US13/213,933 patent/US20110311477A1/en not_active Abandoned
- 2011-08-19 US US13/214,022 patent/US20110311478A1/en not_active Abandoned
- 2011-08-19 US US13/213,819 patent/US20110311476A1/en not_active Abandoned
-
2012
- 2012-06-17 US US13/525,317 patent/US20120251490A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090281047A1 (en) | 2009-11-12 |
| IL208445A0 (en) | 2010-12-30 |
| CN102046180A (zh) | 2011-05-04 |
| ZA201007830B (en) | 2011-07-27 |
| RU2010144744A (ru) | 2012-05-10 |
| US20120251490A1 (en) | 2012-10-04 |
| JP2011516478A (ja) | 2011-05-26 |
| EP2271350A1 (en) | 2011-01-12 |
| CA2757437A1 (en) | 2009-12-03 |
| MX339451B (es) | 2016-05-27 |
| WO2009145841A1 (en) | 2009-12-03 |
| EP2271350A4 (en) | 2011-05-18 |
| US20110311478A1 (en) | 2011-12-22 |
| AU2009251848A1 (en) | 2009-12-03 |
| US20110311477A1 (en) | 2011-12-22 |
| US20110311476A1 (en) | 2011-12-22 |
| MX2010010866A (es) | 2011-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ588668A (en) | Uses of helicin and other glucopyranosyloxy benzaldehydes in the treatment of cancer | |
| AU2016200191B2 (en) | Combination therapy with an antitumor alkaloid | |
| ES2649340T3 (es) | Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer | |
| Nagelkerke et al. | Therapeutic targeting of autophagy in cancer. Part II: Pharmacological modulation of treatment-induced autophagy | |
| Park et al. | The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib | |
| JP2016515619A5 (enExample) | ||
| NZ588913A (en) | Liver cancer drug | |
| BRPI0821616B8 (pt) | composição micelar de copolímero de bloco anfifílico contendo taxano e método para preparação da mesma | |
| IL292245B1 (en) | Polymorphic forms of rad1901-2hcl | |
| BR112012024590A2 (pt) | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos | |
| UY28271A1 (es) | Compuestos químicos | |
| Petrylak | Future directions in the treatment of androgen-independent prostate cancer | |
| JP2012509889A5 (enExample) | ||
| JP2016514135A5 (enExample) | ||
| JP2014511383A5 (enExample) | ||
| HRP20140204T1 (hr) | Oralni oblici doziranja bendamustina | |
| BR112012030658A2 (pt) | formas de dosagem oral de bendamustina e uso terapêutico da mesma | |
| BR112013025517A2 (pt) | uso de 2,3-diidroimidazo[1,2-c]quinazolinas substituídas | |
| JP2011516478A5 (enExample) | ||
| BR112021025394A2 (pt) | Derivados de antraciclina, conjugados de fármaco e molécula de ligação ao alvo, uso de conjugado de fármaco e molécula de ligação ao alvo, método de tratamento de uma doença em um paciente em necessidade de tratamento, e composição farmacêutica | |
| CY1111442T1 (el) | Ενωσεις πιπεριδινης και χρησεις αυτων | |
| EP3003296A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| CL2007002875A1 (es) | Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales. | |
| De Bree et al. | Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination | |
| JP2013511487A (ja) | Ｃｄｃ７阻害剤と抗新生物薬とを含む治療用の組み合わせ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 03 APR 2016 BY AJ PARK Effective date: 20130903 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 APR 2017 BY AJ PARK Effective date: 20160929 |
|
| LAPS | Patent lapsed |